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MUTATIONS IN SIMIAN IMMUNODEFICIENCY VIRUS PROTEASE 
CLEAVAGE SITES 2 AND 12 IMPAIR IN VITRO VIRUS PRODUCTION 
DIANA SHAPOVAL 
ABSTRACT 
The global disease burden due to the HIV/AIDS epidemic continues to rise as efforts to 
prevent or treat the virus are met with more and more challenges. The advent of potent 
antiretroviral treatment options that appear to reduce viral loads to undetectable levels in 
infected patients, are thwarted by HIV’s ability to establish latency and a long term 
persistent virus reservoir. A preventative approach that can establish persistent immunity 
against HIV-1 is urgently needed.  
This study seeks to examine the in vitro effect of a candidate vaccine targeted against 
highly conserved amino acid sequences, known as Protease Cleavage Sites (PCS), in 
HIV-1. Preliminary testing of the vaccine consisting of 20mer PCS overlapping peptides 
was conducted in Cynomolgus macaques and revealed that the highest frequency of 
mutation in two of the twelve sites, were located in the PCS2 and PCS12 regions. 
Sequencing of these mutants isolated from the peripheral blood of vaccinated monkeys 
facilitated the creation, by molecular cloning, of a library viral clones harboring the same 
mutations. These viral clones were then characterized in vitro by determining their 
replicative abilities as compared to wild type virus. While more work is required to 
determine the mechanisms by which these mutations impair viral fitness, the results thus 
far, are informative towards the continued development of this candidate vaccine.  
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INTRODUCTION 
HIV Identification 
The early 1980s marked a period of prolific rise in reports of immunocompromised 
patients across metropolitan clinics with a condition termed “Acquired Immune 
Deficiency Syndrome” (AIDS)[1]. As the number of AIDS cases rose, along with AIDS-
related deaths, the illness was quickly realized to be a global health crisis, resulting in 
much effort expended to identify the causative agent. By April 1984, identical viruses, 
then termed lymphadenopathy associated virus (LAV) and human T-lymphotropic virus 
III (HTLV-III) by different research groups, were identified as the single etiologic agent 
of AIDS. Within two years they were combined under a new name, the human 
immunodeficiency virus (HIV). To date, there have been over 75 million reported cases 
of HIV, 37 million of represent infected individuals as reported in the World Health 
Organization’s 2014 Global Report[2]. 
 
HIV Transmission 
The primary routes of HIV transmission are unprotected receptive intercourse and 
sharing of needles or other tools used for illegal drug injection [3]. Less commonly, the 
virus may be passed from mother to fetus during pregnancy, birth, or via breastfeeding. 
HIV-1 particles in blood, genital and rectal fluids, and breast milk pose the greatest risk 
for viral transmission[1].  
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HIV Phylogeny 
HIV is a member of the Lentivirus genus within the family of Retroviridae a type of virus 
that, in contrast to the central dogma of genetic replication, can “reverse transcribe its 
genome from RNA to DNA and then insert this directly into the host genome, resulting in 
permanent viral archive in the host cell. HIV type-1 (HIV-1) is the predominant strain of 
diagnosed cases owing to its more virulent nature compared to HIV type-2 (HIV-2). HIV-
1 can be divided into groups O, N, and M. Group M (Major) which accounts for 90% of 
cases for HIV-1, has also been divided into multiple clades with some clade-to-clade 
genetic crossover representing “circulating recombinant forms” of virus. Simian 
immunodeficiency virus (SIV) is a virus with high sequence homology to HIV [4, 5] and 
its infection of non-human primates results in a disease syndrome with characteristics 
similar to that of AIDS in humans [6-8]. Therefore, the non-human primate SIV model 
has been instrumental not only in expanding our understanding HIV pathogenesis, but 
also in developing HIV vaccines and therapies. 
 
HIV Genes and Gene Products 
All viral genes are encoded on two identical, positive single-stranded RNA strands that 
are packaged in the nucleocapsid, the core of the mature viral particle. All retrovirus 
genomes, including HIV, contain three major structural genes, gag, pol, and env (Figure 
1) [9]. The HIV genome also contains genes that code for the regulatory proteins, tat and 
rev, which are required to facilitate various aspects of the virus lifecycle. Finally, the 
virus contains a number of accessory genes, vpu (not found in many SIVs), vpr, vif, and 
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nef, that produce proteins that appear to not be absolutely necessary for the virus life 
cycle, although are likely required for efficient virus production. 
Gag 
Gag precursor protein or Gag-Pol polyprotein are translated from the RNA strand by host 
cell ribosomes, differing by a single nucleotide frameshift in the splice site. Gag-Pol is 
cleaved by the viral aspartyl protease to produce separate Gag and Pol precursor proteins. 
These cleavage steps are part of the viral maturation process during and after the budding 
stage. The Gag polyprotein, known at this stage as p55, is further cleaved by the viral 
protease to produce core structural proteins matrix (MA, p17), capsid (CA, p24), and 
nucleocapsid (NC, p7). In the mature viral particle, MA serves as a secondary membrane 
just under the lipid bilayer, forming a substantial barrier. CA comprises the outer shell of 
 
Figure 1. Schematic of HIV genome organization and positions of gene products 
within the virion. Adapted from Frankel and Young 1998 [10]. 
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the cone shaped core that encloses the viral genetic information and the enzymatic 
proteins. NC directly interacts with and stabilizes the two RNA strands. In addition to 
structural function, MA and NC are responsible for localization signals during 
construction of a virion. The MA N-terminal myristate group and basic residues within 
the first 50 amino acids target and directly anchor the Gag and Gag-Pol polyproteins to 
the plasma membrane. The I and L domains found within the NC mediate Gag monomer 
interaction and viral budding, respectively [11]. 
 
Pol 
Pol precursor is processed into protease (PR, p11), reverse transcriptase (RT, p66), 
RNAseH, and integrase (IN, p32)[12]. Without proper processing of the Pol precursor 
into the constituent proteins, the virus will not be able to replicate. To aid the proper 
formation of an infectious virus, the viral protease must release each cleavage product, 
RT reverse must transcribe the viral RNA into cDNA, IN must integrate the viral cDNA 
into the host genome, and RNase H must degrade the viral RNA during reverse 
transcription[13]. A functional protease primarily required to facilitate the morphogenesis 
of immature viral particles to mature, infectious virions during the budding from the host 
cell membrane[14]. 
 
Env  
The Env protein similarly requires processing by a host cell protease into gp120 and gp41 
proteins. The outermost surface of the viral particle is a lipoprotein membrane, embedded 
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with glycoprotein complexes each of which are trimers of an outwardly protruding 
surface glycoprotein (SU, gp120) loosely bound to a transmembrane glycoprotein (TM, 
gp41)[12, 15]. Each complex appears as a “knob” or “spike” on electron micrographs. 
These “spikes” arise from the co-translational processing and insertion of the entire Env 
protein into the host cell via the rough endoplasmic reticulum. This polyprotein 
undergoes trimerization in the ER, cleavage into gp120 and gp41 in the Golgi, and 
ultimately, vesicular transport to the cell plasma membrane[16].  
 
The gp120 surface subunit is involved in binding to its receptor, CD4, and coreceptor, the 
chemokine receptors CXCR4 and CCR5, as well as recognition during antibody 
neutralization. This complex acts as a surface antigen, thus playing a key role in 
determining viral tropism. Additional proteins acquired from the host cell’s plasma 
membrane can become embedded in the virion’s lipid bilayer during the budding stage, 
or conversely the glycoprotein complex can be shed[16]. While previous research 
suggests an average of 72 complexes are initially embedded in the viral membrane, more 
recent data suggests that many of the complexes are not shed, but rather retained inside 
the host cell[12]. This seems to account for why only 7 to 14 complexes are typically 
found on the surface of mature virions. The mature viral particle is released into the 
extracellular space and is termed as “cell-free” virus while viral components found in the 
infected host cell are known as “cell-associated” virus[17].  
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Nef 
Nef protein is one of the regulatory proteins required for high levels of viremia, common 
to HIV-1, HIV-2, and SIV alike[18]. This protein plays three paramount roles in viral 
infection. First, Nef activates target T cells, a step without which infection would be 
abortive[19, 20]. Secondly, the protein establishes viral persistence by downregulating 
surface recognition modalities including both MHC class I and CD4 molecules. These 
signaling molecules are endocytosed and degraded in lysosomes. Finally, the Nef-
mediated downregulation of these surface recognition molecules leads to increased 
evasion of cytotoxic T cell detection, and thereby avoids apoptosis. Several studies of 
mutations in the Nef protein have also shown its correlations to high viral load and 
pathogenicity[18, 20]. Interestingly, as an early expressed transcript the nef mRNA 
accounts for three quarters of mRNA present during early viral replication [21]. 
 
HIV Life Cycle 
The first step of HIV entry is receptor recognition and fusion with the cell membrane 
(Figure 2). The primary receptor for HIV is the CD4 molecule. After CD4 engagement 
with Env, there is a conformation change in the viral envelope, allowing binding to the 
co-receptors, predominantly CCR5 and CXCR4. This is followed by membrane fusion, 
delivering the viral core directly into the cell cytosol. Because of these receptor and co-
receptor requirements, HIV primarily infects CD4+ T cells, along with monocytes, and 
macrophages, dendritic cells, and microglial cells[13, 18]. Some CD4-negative cells may 
also be infected by cell-to-cell fusion[22]. 
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Figure 2. Viral Life Cycle from infection to HIV-1 budding. This schematic shows 
steps from infection of the CD4+ T cell at the top, through viral integration and 
replication within the host T cell, to assembly, budding, and extracellular maturation at 
the bottom. Adapted from Turner et al 1999[11]. 
 
Once in the cytosol, the RNA-containing capsid is uncoated, releasing the RNA genome 
and associated proteins into the cytosol in a protein bound state referred to as the pre-
integration complex (PIC). The viral reverse transcriptase (RT) uses dNTPs in the host 
cytosol to reverse transcribe the single stranded viral RNA into double stranded cDNA[9]. 
The virus RT is very error-prone (low fidelity), which largely accounts for the numerous 
mutations the viral genome acquires with each round of reverse transcription[23]. RT also 
degrades the RNA using its ribonuclease activity, allowing for synthesis of double 
stranded DNA (dsDNA). The dsDNA fragments associated with the viral integrase, and 
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other proteins in the PIC, are then transported and integrated into the host genome using 
the nuclear localization and enzymatic activities of the viral integrase. This process is the 
hallmark of all retroviruses. While all other retroviruses require the cell to be actively 
dividing for successful integration, HIV-1 (and SIV) are unique among retrovirus in that 
they can integrate into the DNA of non-dividing cells [24].  
 
Once the genome has been integrated successfully, the host cell machinery will  
transcribe and translate the viral genes and proteins as if they are its own. The viral 
protease plays a critical role at this stage by cleaving the viral polyprotein into the final 
products that are required for virion assembly[14]. The protease targets are specific, 
conserved amino acid sequences found in the precursor polyproteins, known as protease 
cleavage sites (PCSs). For HIV, 12 such sites exist and their locations within the RNA 
are shown in Figure 3. Cleavage at all 12 sites is required for viable virion production 
[25]. The cleaved proteins then associate with the unspliced viral RNA in the cytosol at 
the plasma membrane to form the core particle. The structural and enzymatic proteins are 
assembled into the final immature virion, which then buds off from the plasma 
membrane.  
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Figure 3. Schematic representation of HIV structural protein cleavage by viral 
protease. Gray bars indicate the different reading frames that the genes are located on. 
Blue bars indicate the polyproteins before cleavage. Connected yellow, pink, and orange 
bars indicate the positions of the final proteins within the polyprotein before cleavage. 
Disconnected yellow, pink, and orange bars indicate the final products after cleavage. 
Numbers below cleavage products indicate designation of cleavage site number. Adapted 
from de Oliviera et al. 2003 [26] 
 
HIV Disease Course 
Due to the preferential infection of activated CCR5+CD4+ T cells and the abundance of 
these cells at mucosal sites, after a week of infection, up to 20% of gut-associated CD4+ 
T cells are infected and up to 80% are destroyed [8, 27, 28]. Virus replication in the blood 
peaks between day 14-21 and then declines [29-31], reaching a steady state two to six 
months after infection [32, 33]. This decline of virus replication is associated with a 
rebound in CD4+ T cell numbers that remain steady for many months and the increase in 
antiviral immune responses. But the levels of CD4+ T cells eventually begin to decline 
slowly over the following years and this is associated with a decay and dysfunction of 
many other aspects of the immune system that eventually lead to AIDS [34, 35]. 
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Correlates of Protection 
From studies in both HIV-1-infected humans and SIV-infected monkeys, we have 
developed an understanding of the factors that are involved in protection from infection 
and disease progression.  
 
Most viruses are sensitive to neutralizing antibodies. Therefore, it is not surprising that 
neutralizing antibodies have also been associated with SIV and HIV control. Depletion of 
B cells in SIV-infected rhesus monkeys inhibited production of neutralizing antibodies 
and was associated with an increase in viral load [36]. Additionally, passive transfer of 
neutralizing antibodies to rhesus monkeys prior to challenge prevents infection [37-39].  
Many lines of evidence suggest that CD8+ T cells also play a substantial role in control 
of viral replication. There is a temporal association between the decrease in viral load 
during acute infection and the rise in virus-specific CD8+ T cells [40, 41]. Additionally, 
antibody-mediated CD8+ cell depletion in rhesus monkeys either before or during SIV 
infection was associated with a substantial rise in viral load during acute infection and 
more rapid disease progression [42, 43].  
 
There also is a strong correlation between certain major histocompatibility complex 
(MHC) class I alleles, in both humans and rhesus monkeys, and superior viral control. 
This suggests that MHC class I presentation of viral epitopes to CD8+ T cells likely plays 
a role in viral control and that certain alleles are more protective than others [44]. 
Additionally, mutations in the viral sequences that result in loss of recognition by the 
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CD8+ T cells that leads to disease progression preferentially occur within MHC class I-
restricted viral epitopes [45, 46]. This suggests that the epitope-specific CD8+ T cells are 
applying immune pressure. 
 
HIV Treatment 
Since the discovery of HIV in the 1980’s, high demand for development of a prophylactic 
or curative agent for HIV has been met with several challenges. The most significant 
challenge among them is the virus’ genetic diversity, allowing it to evade both immune 
detection and antiviral drugs. The establishment of this vast genetic diversity is primarily 
due to the extremely low fidelity of viral RT with an average error rate of up to 6.7x10-4, 
or 1 error per 1700 nucleotides [23, 47]. While replicative errors play a prominent role in 
introducing mutations, genetic diversity is also attributed to high viral turnover rate [48], 
host immune pressure, and constraints on variation in certain conserved sequences [49, 
50]. The accumulation of errors creates an immense variety of both viable and nonviable 
virus. Host production of antibodies, recognition by cytotoxic T cells, or HIV-specific 
drugs can select for mutants that maintain high fitness while escaping from the immune 
pressure. 
 
Currently, the most common and effective course of HIV-1 treatment is highly active 
antiretroviral therapy (HAART), an acronym for combinations of drugs that 
simultaneously target multiple aspects of the HIV lifecycle. HIV antiviral drugs fall into 
the categories of reverse transcriptase inhibitors: nucleoside analog reverse transcriptase 
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inhibitors (NRTIs) and non- nucleoside analog reverse transcriptase inhibitors (NNRTIs), 
protease inhibitors, entry inhibitors, integrase inhibitors, and fusion inhibitors[51]. While 
providing combinations of these drugs reduces the rate of developing viral mutations that 
confer drug resistance, resistance can still occur, illustrating the need for more permanent 
approaches to HIV infection such as vaccination or cure. Figure 4 lists the most frequent 
viral mutations that occur in response to current antiviral drugs that allow the virus to 
maintain a pathogenic level of fitness.  
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Figure 4. Mutations frequently acquired in response to common HIV therapeutic 
agents. Amino acid mutations in the integrase (A), reverse transcriptase (B), envelope 
(C), and protease (D) resulting from nonsynonymous nucleotide changes. Numbers 
within colored bars indicate position within viral protein. Letters above each colored bar 
indicate wildtype amino acid at the indicated position. Letters below the colored bar 
indicate the frequent amino acid changes. Figure adapted from Wensing et al. 2015 [52]. 
 
 
After prolonged ART, patients typically reduce their peripheral blood plasma viral load 
to undetectable, or near undetectable levels (<50 copies/mL). However, once the patient 
is taken off ART, the virus often resumes replication and plasma virus can be detected as 
early as three days following drug cessation[53]. This recrudescent virus is derived from 
a latent viral reservoir that had been established during primary infection. Some virus-
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infected cells become quiescent and thus do not actively produce virus. Not only do these 
cells exist invisible to the immune system, but ART does not impair their existence. Why 
only some cells enter latency is undefined in the field of study but virus production will 
occur only after activation of the quiescent cell[54].  
 
One of the newest therapeutic approaches, colloquially termed “shock and kill,” aims to 
eliminate this latent viral reservoir. It is thought to require two components: 1) a “shock” 
component that would activate cell harboring latent virus to being active virus production 
and 2) a “kill” component that would enhance the immune systems efforts to kill infected 
cells[55]. Elimination of this viral reservoir is perhaps the most significant challenge in 
HIV therapeutic efforts.  
 
HIV Vaccines 
The traditional approach for viral vaccines has been to introduce a foreign element to the 
immune system in a manner that stimulates an adaptive immune response (humoral 
and/or cell-mediated). The vaccine initiates an innate response followed by a highly 
specific adaptive response. During the adaptive phase, memory T cells are generated that 
are primed to provide an enhanced immune response upon future encounters. The type of 
vaccine administered to create immune memory depends on a viral or bacterial pathogens 
as well as the type of immune response it will elicit[56]. Strategies that are used in 
currently-licensed viral vaccines include live attenuated virus, whole inactivated virus, 
virus subunits, and virus-like particles. Additional approaches being investigated, but 
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currently not licensed for any infectious disease indications, include replicating vectors 
(viral or bacterial), peptides, and DNA[57]. Unlike most vaccine approaches however, 
HIV vaccine development seeks to prevent infection rather than disease because of the 
virus’ ability to establish post-infection latency.  
 
The first clinical trials of HIV vaccines, VAX004, occurred in 1998 with AIDSVAX 
B/B; an alum-adjuvented recombinant gp120 subunit vaccine [58]. This was followed in 
1999 with a clinical trial (VAX003) with the modified counterpart, AIDSVAX B/E [59]. 
Following VAX004 and VAX003, RV144 was the first “prime boost” type of vaccine 
regimen to be evaluated for HIV, consisting of a carnypox vector prime (ALVAC-HIV) 
and the AIDSVAX B/E construct as the boost [60]. RV144 generated much attention as 
initial analysis showed an estimated vaccine efficacy of 31.2% for acquisition prevention. 
However, protection appeared to wane rapidly. Additional prime-boost regimens have 
since been evaluated; however have yet to yield promising protective effects.  
 
Viral Escape 
One of the greatest challenges to development of effective HIV vaccines and therapies is 
the virus’ ability to generate and tolerate immune escape mutations. These escape 
mutations in the viral genome, which allow the virus to evade both humoral and cellular 
immune responses, arise randomly are attributed to the virus’ error prone reverse 
transcriptase that facilitates an extraordinarily high mutation rate [23]. The accumulation 
of mutations creates an immense pool of both viable and nonviable virus, and mutations 
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which incur significant fitness costs are unable to persist. During the natural course of 
infection, HIV triggers immediate CTL-mediated killing of infected cells during the 
innate immune response. Acute infection is marked by a rapid decline in CD4+ cell count 
due to CTL targeting, followed by establishment of the viral set point where both killing 
of the productively infected host cells and plasma viral load seem to balance one another 
and taper off. One study suggests that this reduction in both CD4+ T cell and viral load 
levels occurs due to presence of mutants with selection advantage that can avoid CTL 
pressure [61]. These cells create a cellular immune pressure by recognizing viral antigens 
on the surface of virus infected cells and targeting them for destruction. Chief amongst 
these targeted cells are CD4+ T cells but also include macrophages, dendritic cells, and 
some other antigen presenting cells. Only virus whose epitopes have acquired mutations 
that can successfully avoid CTL detection will persist. 
 
As infection progresses into the adaptive immune response, production of neutralizing 
antibodies (nAbs) against both cell-free and cell-associated viral epitopes begins. After as 
early as day 52 post-infection, nAb’s begin to appear in plasma marking successful 
seroconversion[62]. A similar pressure seen in CTL targeting is exerted selecting for 
mutants that can avoid nAb recognition.  
 
Several studies have been able to isolate the mutant viruses which preferentially sustained 
despite potential fitness costs. These variants, differing from the founder virus primarily 
in the epitopes found on gp120 Env and p24 Gag, were investigated on the basis of their 
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ability to achieve an escape-fitness balance in vivo [62]. Fitness levels are determined 
based on the kinetics of a single viral species’ ability to successfully infect and replicate 
in target cells as compared to the wild type or founder form. This study found that 
multiple epitopic mutations could even have a compensatory effect that serves to increase 
fitness.  
 
In a similar manner to immune selective pressures from CTLs and nAb, pressure from 
antiviral drugs selects for variants that contain escape mutations in the drug target sites. 
In some instances, studies have determined that founder virus mutations can revert to a 
form sensitive to host HLA I alleles prior to transmission [63]. Both introduction of new 
mutations and reversion events due to immune pressure contribute to HIV evolution in 
vivo. Some of the greatest fitness costs due to random mutation are incurred in conserved 
protein or nucleic acid sequences whose integrity is paramount in the viral infectivity and 
life cycles[64]. These restricted regions are therefore of great importance in both vaccine 
and cure approaches.  
 
Current investigation  
For HIV, although most agree that a vaccine capable of generating high titers of broadly 
neutralizing antibodies would be ideal, creating such a vaccine has been challenging [65-
67]. Considering the role that CD8+ T cells play in controlling HIV and SIV, much effort 
has been directed at developing a vaccine that would elicit virus-specific CD8+ T cells 
that could control infection and possibly induce sterilizing immunity. Indeed, rhesus 
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monkeys receiving vaccines designed to induce virus-specific CD8+ T cell responses 
were often able to control virus more efficiently than unvaccinated controls [68-73]. 
However, CD8+ T cell-based vaccines are complicated by the ability of the virus to 
mutate and select for CD8+ T cell epitope escape mutations. Therefore, is has been 
proposed that CD8+ T cell-based vaccines should target conserved regions of the virus 
that cannot tolerate mutation at the cost of destroying the ability of the virus to replicate.  
  
A study by Luo et. al. demonstrated that the twelve PCSs in the HIV genome are highly 
conserved across HIV clades (Figure 5) and that multiple major histocompatibility class I 
 
Figure 5. Amino acid sequence conservation of the 12 HIV protease cleavage sites. 
Amino acid sequences flanking all 12 HIV protease cleavage sites are shown. Consensus 
sequence is the first listed in each section and is in bold. Common amino acid differences 
observed within clades are shown in bold red letters. Adapted from Lou et al 2013 [74]. 
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(MHCI) epitopes exist in PCS regions across multiple genetically diverse populations 
[74]. This suggested that PCSs may provide an immunogenic CD8+ T cell vaccine target 
that would also be robust despite the great MHCI diversity worldwide. 
 
 
Figure 6. Frequency of common SIV amino acid mutations within protease cleavage 
site regions in monkeys following vaccination. Blue PCS2 mutations. Black, PCS12 
mutations. V=vaccination, C=controls. Numbers below V/C indicate amino acid position 
within indicated PCS. Specific amino acid mutations as compared to wild type are 
indicated below position. Y axis displays the sum of PCS mutation frequencies between 
1-17 weeks post SIV challenge. The comparison of the values from the groups of animals 
was determined using a non-parametric one-way ANOVA Kruskal-Wallis test with 
Dunn's multiple comparison test or the Mann-Whitney test. The amino acid mutations 
less than 10% in other PCS sites are not included in the analysis [75]. 
 21 
A proof-of-concept vaccine study was subsequently conducted in Cynomologus 
macaques. A peptide-based vaccine was developed that consisted of overlapping peptides 
covering the 12 PCSs encoded by a modified vesicular stomatitis virus (VSV) vector. 
Following vaccination, monkeys were challenged with SIV. Analysis of SIV sequences 
during acute and chronic infection revealed that several mutations in PCS regions 
developed, some preferentially within the vaccinated group-three of these mutations were 
found in PCS2 and two in PCS12 (Figure 6) [75]. 
 
The fact that all 12 PCS sites are highly conserved among all HIV-1 clades suggests that 
the conservation of these sequences is required to maintain the function of the cleavage 
sites and therefore critical virus replication. The abovementioned study demonstrates that 
when under immune pressure, the virus can indeed develop mutations in these regions 
and maintain some, albeit reduced, replicative capacity. However, it is possible that by 
acquiring these mutations, that the virus incurs a fitness cost. Indeed, analysis of the 
correlation of the presence of each of dominant mutation with plasma viral load revealed 
that some of these mutations were in fact associated with viral load. Interestingly, while 
PCS12 (-8) was significantly negatively correlated viral load, PCS2 (-8) was positively 
correlated with viral RNA levels in the blood (Figure 7).  
 
The above data suggested that these mutations in PCS may alter viral fitness. Therefore, 
the present study sought to investigate if and to what extent the mutations in PCS2 and 
PCS12 impact SIV replication fitness. We hypothesized that most of these mutations 
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when introduced into SIVmac239 would result in some reduced replicative capacity as 
compared to SIVmac239, and that virus harboring several mutation would exhibit either 
an additive or a synergistic reductions in replicative prowess. Based on the in vivo data, 
we expect that either the PCS12 G→R or G→E mutation may aid virus replication. 
Understanding the nature of the virus when mutations that occur within the PCS regions 
will further our understanding of virus sequence evolution and inform the development of 
T cell-based HIV-1 vaccine strategies. 
 
Figure 7. Correlation between the major PCS amino acid mutation and changes in 
plasma viral load in the vaccine group. Correlation matrices were generated using 
Spearman nonparametric correlation to compute the correlation coefficient for each pair 
of variables including PCS amino acid mutations (PCS2: -8, -7, and -6 and PCS12: -8) 
and plasma SIV RNA levels in the vaccine group. Adapted from Alcoreza 2015[75]. 
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METHODS 
Construction of single and double PCS mutant SIV clones 
The PCS2 and PCS12 regions from the wildtype SIVmac239 clone were subcloned into 
the plasmid pSP73. The vector containing the PCS2 region (pSP73-PCS2) and PCS12 
region (pSP73-PCS2) were subject to site-directed mutagenesis to introduce the specified 
single amino acid changes using the Stratagene Quickchange II kit, as specified by the 
manufacturer. These point mutations were confirmed by sequencing. The plasmids 
containing the mutated sequences were amplified in E. coli and purified using Qiagen 
Mini and Maxi Prep Kits.  
To create the double mutant constructs, the five single mutant clones were run on an 
agarose gel to confirm that the bacteria had taken up the mutant viral fragment. The 
single mutants were cut out from the gel, isolated, and treated with ligase to allow the two 
mutagenized fragments to come together. Each of these double mutant clones were then 
grown in bacteria again, purified using the Mini/Maxi kit, and run on the gel to determine 
which clones were successful. Finally, both single and double mutant clones were 
reinserted into SIVmac239.  
Transfection 
The day before transfection, 293FT cells were counted and seeded to wells or flasks. 
Cells were incubated overnight at in an incubator at 37°C with 5% CO2. The following 
day, cells were transfected at 75% confluency. Subsequently, each DNA construct was 
combined with pure DMEM, without antibiotic. When preparing samples for transfection 
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in 6-well plates, 3 µg of DNA was added to DMEM to a final volume of 0.5 mL. When 
preparing samples for transfection in T175 flasks, 5 µg of DNA was used in the same 
final volume. The mixture was incubated for 5 min. A solution of  5 µL Lipofectamine 
per µg DNA was prepared in 500 µL DMEM and added dropwise to the DNA, mixed, 
and incubated at RT for 20 min.  
 
During the incubation of DNA with Lipofectamine, the cells in plates/flasks were washed 
twice with DMEM. 2.5 mL of fresh DMEM was added, followed by the 1 mL of the 
Lipo-DNA complex. The plates/flasks were returned to the incubator and rocked gently 
once every hour for five hours. After 5 hrs, all media was aspirated and replaced with 10 
mL fresh DMEM with FBS and antibiotics (penicillin and streptomycin). After 36-48 
hours, the supernatant and/or cells were harvested.  
 
Collection of cell-free and cell-associated virus for virus quantification 
After the 48 hr incubation of transfected cells, the supernatant was harvested and 
centrifuged at 3000rpm. The purified supernatant was overlayed on 20% sucrose and 
spun in an ultracentrifuge at 40,000rpm for one hour, then stored at -20°C until ready for 
use. The cells adhered to the flask were liberated with trypsin and washed twice with 
10mL PBS. The cell suspension was stored at -80°C until use. The cells were then 
thawed on ice and lysed with 800uL ice cold lysis buffer for 20min at 4°C. Both the 
supernatants and cell lysates were used to quantify both viral RNA copy number and p27 
protein content. 
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Quantifying Virus by RT-PCR  
RNA was extracted from both the triplicates performed in 6-well plates from the first 
transfection and from the supernatant of the second transfection, according the 
instructions in the QIAamp Viral RNA Mini Kit. Viral RNA was then quantified using 
quantitative real-time CR essentially as described previously [76]. Briefly, RNA was 
isolated by phenol-chloroform purification followed by ethanol precipitation. All purified 
RNA preparations were quantified by optical density. Quantitative RT–PCR was 
conducted in a two-step process. First, RNA was reverse transcribed in parallel with an 
SIV-gag RNA standard using the gene-specific primer sGag-R5’-
CACTAGGTGTCTCTGCACTATCTGTTTTG-3’. All samples were then treated with 
RNase H (Stratagene) for 20 min at 37 °C. Primer sequences were adapted from those 
described [76] including the forward primer sGag-F: 5’-P: 5’-
CTTCCTCAGTGTGTTTCACTTTCTCTTCTGCG-3’, linked to Fam and BHQ 
(Invitrogen). All reactions were carried out on a 7300 ABI Real-Time PCR system 
(Applied Biosystems) in triplicate according to the manufacturer’s protocols. 
 
Quantifying Virus by ELISA 
The supernatants collected from the transfected cells were thawed for use in this assay. 
Levels of p27-CA antigen present in the supernatants were quantified using the 
ZeptoMatrix SIV p27-CA Antigen ELISA kit according to the manufacturer protocol. 
RNA level was used to determine the dilutions for each sample needed to create a 
standard curve.  
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RESULTS 
To initiate these studies, we first generated mutant constructs using the full-length 
infectious clone of SIVmac239. We then used these WT or mutant expressing constructs 
to produce viral stocks, comprising the WT or 10 PCS mutants by transfecting 293FT 
cells (Table 1). Two of these transfection-derived PCS mutant stocks (PCS-M1 and -M2) 
contain single amino acid mutation in PCS12 region, which cleaves Nef, PCS-M3-5 
contains single amino acid mutation in PCS2 cleavage site between p27-CA and the P2 
protein. The remaining five transfection-derived PCS mutant stocks (PCS-M6-10) 
contain two amino acid mutations, one in the PCS2site and the other in PCS12 region. 
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To evaluate the virion content of vRNA and protein of each mutant, we first determined 
the viral RNA and p27 CA protein content in six of the virus stocks including WT and 5 
PCS mutants harboring a single amino acid change (PCS-M1-5). Two PCS 12 mutant 
stocks, PCS-M1 and –M2 contained 3.40 × 109 and 3.37 × 109 RNA copies/ml and 62 
and 61 ng p27/ml, respectively (Figure 8). No significant differences in these two 
Table 1. Viral Stocks evaluated in this study. One amino acid change in each of three 
sequential codons for PCS2 (-8, -7, and -6). Two single mutations in same codon for 
PCS12 (both -8). Mutations of amino acids as compared to those coded for in wild type 
indicated in bold face.  
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measurements were observed between WT or either PCS12 mutant viral stock. However, 
the three PCS2 mutant virus, PCS-M3-5 contained significantly lower encapsidated viral 
RNA. This vRNA reduction ranged between 6.83 × 107 and 1.31 × 109 RNA copies/ml 
and 0.9 to 13 ng p27/ml. 
 
Figure 8. Virus content of transfection derived SIVmac239 PCS single mutant 
stocks. Quantification of viral RNA copy number by qRT-PCR (filled bars) and p27-CA 
protein content (empty bars) by enzyme-linked immunosorbent assay (ELISA) in WT 
and five PCS mutant stocks each containing a single amino acid mutation in either PCS2 
or PCS12 region. RNA copy data represent the mean values for each sample assayed in 
duplicates and each virus sample was harvested from culture supernatant of each viral 
stock in triplicates. The p27 data represent mean values for each sample at 3 or more 
dilutions within the linear range of the dilution series. The comparison of the values from 
the virus stocks was determined using one-way ANOVA with post test for multiple 
comparison. Significant differences between WT and PCS mutant stocks with single 
amino acid mutation are e indicated by asterisks (*P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001). 
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 We next evaluated the viral RNA and p27 CA protein content in the remaining five PCS 
mutant stocks (PCS-M6-10) that contain two amino acid mutations; one in PCS2 and the 
other in PCS12 region. Although the relative differences in both values of these stocks 
were similar to those of WT, there were apparent double mutation effects on the gain and 
loss of these values when they were compared between single and double mutant viral 
stocks (Figure 9).  
  
 
Figure 9. Virus content of transfection derived SIVmac239 PCS double mutant 
stocks. Quantification of viral RNA copy number by qRT-PCR (filled bars) and p27-CA 
protein content (empty bars) by enzyme-linked immunosorbent assay (ELISA) in five of 
PCS mutant stocks, which contain two amino acid mutations, one in PCS2 and the other 
in PCS12 region. A) PCS2(-8)/PCS12(-8), B) PCS2(-7)/PCS12(-8), and C) PCS2(-
6)/PCS12(-8). RNA copy data represent the mean values for each sample assayed in 
duplicates and each virus sample was harvested from culture supernatant of each viral 
stock in triplicates. The p27 data represent mean values for each sample at 3 or more 
dilutions within the linear range of the dilution series. The comparison of the values from 
the virus stocks was determined using an one-way ANOVA with post test for multiple 
comparison. Significant differences between each PCS mutant stock with single amino 
acid mutation in PCS2 and PCS mutant stocks with two amino acid mutations, one in 
PCS2 and the other in PCS12 region were indicated by asterisks (*P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001). 
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When either of the PCS12 mutations were combined with either the PCS2 -8 or PCS2 -7 
mutations, there was an enhanced impairment of virus production, compared to the 
impairment seen with PCS2 -8 or PCS2 -7 alone (Figure 9A and 9B). However, the 
addition of either of the PCS12 mutations to the PCS2 -6 resulted in a partial recovery of 
virus production (Figure 9C). The viral RNA and p27 CA protein measurements were 
discordant for the M10 mutant. 
 
FUTURE WORK 
In order to characterize these PCS mutant clones further, additional analyses must be 
performed. The present study did not quantify the amount or nature of the Nef protein. 
Effects of the PCS mutations on Nef production could be evaluated by Western blot. 
Considering that neither of the PCS12 mutants exhibited significant reduction in virus 
production, we may not expect substantial reductions in Nef protein production when 
measured by Western blot. We would also not expect any of the PCS2 mutants to affect 
Nef production. However, it would be particularly interesting to see what effect the PCS2 
-6 / PCS12 double mutant, that showed discordance RNA/p27 results, had on Nef protein 
production. It also remains possible that while mutations in PCS12 do not affect in vitro 
virus production, they may affect substantially the course of infection in vivo as Nef plays 
a critical role in the virus’ evasion from the host immune response, contributing to higher 
viral loads [77]. 
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To continue the evaluation of the PCS vaccine on SIVmac239 fitness, competitive fitness 
assays will be carried out as described by Anastassopoulou et al [78]. However, we have 
adapted the described HIV-specific assay for use with SIV isolates. In selecting the 
appropriate assay for viral fitness determinations, there were a number of limitations and 
concerns. A few of these experimental decisions are shown below (Figure 10). For 
example, using conventional RT or p24 antigen capture assays to distinguish two similar 
SIV isolates in a single culture is not currently feasible [79].    
 
 
Figure 10. Practical considerations in the design of a competitive viral fitness assay.   
Schematic representation of each of the 5 aspects to be considered in the selection of the 
most appropriate assay conditions including 1) culture environment, 2) virus isolate, 3) 
inoculum titration, 4) assay specifics, and 5) experimental endpoints 5. Adapted from 
Chen et al 2005 [80].     
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However, it is possible to make this distinction using a comparator virus that contains a 
unique region that can be used to differentiate itself from other virus isolates. In order to 
provide a more accurate portrayal of in vivo viral fitness, a competitive fitness assay 
using mutant SIV and wild type SIVmac239, which represents the founder virus, was 
developed based on the assay used by Anastassopoulou et al [78]. In this assay real- time 
quantitative PCR (QPCR) is used to quantify competing viruses using probes that 
differentially target silent mutations artificially created on the vif gene. Our assay will 
consist of a wild type SIVmac239 containing silent mutations to be our comparator virus 
versus the SIVmac239 clones generated for the present study. 
 
Figure 11. General setup of a virus competition assay. Fitness (W) can be calculated 
by the proportion of virus in a dual infection (fo ) divided by its initial level in the 
inoculum (io). The relative fitness difference (Wdiff) can be determined by the ratio of the 
more fit (Wm) and less fit (WL) virus. Figure adapted from Quinones-Mateau and Arts, 
2003 [81]. 
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DISCUSSION 
 
A proof-of-principle study evaluating the immunogenicity of peptides covering the 12 
SIV protease cleavage sites had identified the evolution of compensatory mutations at 
multiple residues within PCS regions. Of these, 5 were found at an increased frequency in 
vaccinated monkeys compared to control monkeys (positions -8 P→R, -7G→D, and -
6Q→E) and PCS12 (-8G→R and -8G→E). Successful cleavage at all 12 SIV (and HIV) 
PCS are thought to be required for an infectious virion. Therefore, the evolution of these 
mutations in these conserved regions in response to vaccine-induced immune pressure 
was surprising. The present study sought to investigate the impact of these mutations on 
viral fitness by generating SIV mutant clones containing each of these mutations in 
isolation as well as in combination. 
 
Our data showed that neither of the single mutations in PCS12 alone impacted in vitro 
viral production, as measured by either viral RNA production or p27-CA production. 
This is somewhat surprising as the data from vaccinated monkeys carrying these 
mutations show a negative correlation between the presence of these mutations and 
plasma viral load [75], suggesting that these mutations might have a negative impact on 
virus replication. It is possible that that the PCS12 mutations in isolation do not confer 
reduced replication but that in vivo they must act in concert with other mutations within 
the genome. To determine this, sequence analysis should be performed to identify 
additional mutations that are associated with these PCS12 mutations when in the presence 
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of low viral load. Alternatively, these PCS12 mutations may not impair replication at all, 
but instead may be tightly linked to other mutations that do impair replication. 
 
All three of the single PCS2 mutations negatively impacted in vitro viral production to 
some degree. This was expected for the PCS2 -8 mutation, as this mutation was 
associated with reduced plasma virus in vaccinated monkeys. However, it was somewhat 
surprising that the PCS2 -7 and -6 mutations, which were not correlated with viral load in 
the monkeys, had more severe detrimental effects on in vitro virus production than the 
PCS2 -8 mutation. Similar to the discordance between in vivo and in vitro data of the 
PCS12 mutants, it is possible that in vivo the PCS2 mutations are associated with 
additional compensatory mutations in other regions of the genome that are contributing to 
the virus replication phenotype. For example, mutations in the protease that can alter its 
relative activity among the difference PCS regions. Indeed, it has been demonstrated that 
the protease and its substrates can co-evolve in response to selective pressures to remain 
functional [82]. Additional sequence analysis is necessary to determine if such 
compensatory mutations are present in the vaccinated monkeys. If such additional 
compensatory mutations are identified, they could be introduced into SIVmac239 clones 
and their effects on virus production, alone and in combination with the already-
identified PCS2 mutations, could be assessed. 
 
The double mutants evaluated in this study modified the effects of the PCS2 single 
mutants. The addition of either the PCS12 -8G→R or G→E mutants to the PCS2 -8 
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mutant had a synergistic negative effect on viral replication, resulting in reduced virus 
production compared to either of the PCS2 or PCS12 mutants alone. A similar effect was 
observed when the PCS12 -8 G→E mutant was combined with the PCS2 -7 mutant. 
However, we were surprised to find that the addition of either the PCS12 -8G→R or 
G→E mutants to the PCS2 -6 mutant actually partially rescued the virus production 
defect that the PCS2 -6 mutant alone had conferred.  
 
The finding that the PCS12 mutants were able to modify the effect of the PCS2 mutants 
is quite remarkable considering not only that the PCS12 mutants alone appeared to have 
no effect but also because these two PCS sites are quite distant from each other (see 
Introduction Figure 3). Considering this, it is unlikely that the nature of the interaction is 
simply an additive/synergistic effect on protease efficiency. Instead, the PCS12 mutation 
may interfere with a viral RNA tertiary structure that is critical for virus replication. 
Indeed, the tertiary structure of HIV RNA, in which interaction between RNA residues 
located at distant sites within the linear genome, are critical for certain steps of the virus 
life cycle, such as genome packaging [83]. 
 
There did appear to be discordance in results of the effect of the PCS2 -6/PCS12 G→E 
(M10) between the viral RNA measurements and the p27-CA measurements (Figure 
9C). One possible explanation is that the capsid protein was produced at levels similar to 
that suggested by the viral RNA measurements, but that the presence of these mutations 
alters the conformational structure of the p27 protein resulting in loss of epitope 
 37 
formation. In this case, while the protein would be present, the antibody would not be 
able to recognize it. This is consistent with the fact that the antibody used to detect p27 in 
these studies recognizes a conformational (rather than linear) epitope on the capsid 
protein. Alternatively, this discordance may be the result of a technical error. These 
experiments require additional replicates for confirmation. 
 
Interestingly, while the PCS12 mutations rescued the viral defects conferred by the PCS2 
-6 mutation, it did not completely restore “WT-like” incorporation of vRNA or p27-CA 
levels it. This suggests that while the PCS12 mutations likely serves to partially 
compensate the debilitating mutations in PCS2, there may be other mutations in disparate 
regions of the viral genome. Indeed, these mutations may have developed in the monkeys 
but additional sequence analysis would be needed.  
 
Additional compensatory mutations, required to fully restore virus replication could be 
accomplished by in vitro forced replication experiments [84]. In these experiments 
viruses containing the PCS2 -6 and PCS12 mutations would be grown and passaged in 
vitro. These viruses would initially replicate poorly, as indicated by their poor virus 
production in the present study. However, additional mutations would develop during 
passaging and those mutations that confer a growth advantage should outcompete the 
original virus. After multiple rounds of passaging, the virus sequence would be analyzed 
and the additional compensatory mutations that conferred complete rescue of viral 
replicative fitness could be identified. 
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CONCLUSION 
The present study demonstrates that mutations in SIV protease cleavage sites negatively 
impact in vitro virus production and that the effects of some mutations are synergistic. If 
these mutations similarly impair viral fitness and are responsible for reduced viral 
production in vivo, then a vaccine strategy targeting conserved PCS may provide a 
promising vaccination strategy. Additional studies would be needed to determine which 
mutations or combinations of mutations are the most detrimental to viral replication and 
subsequently which vaccine peptides are responsible for inducing these mutations. 
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